Clinical trial Recruiting at 1 site Interventional Ages 21 Months to 60

Sphenopalatine ganglion block to improve the surgical field during endoscopic pituitary removal

Official title: The Efficacy of Ultrasound Guided Sphenopalatine Ganglion Block as Adjuvant to General Anesthesia Regarding the Quality of Surgical Field in Trans-Sphenoidal Endoscopic Hypophysectomy: A Randomized Controlled Trial

Run by Cairo University · NCT07569952 · Data updated 2026-11-12

This trial will try an ultrasound-guided sphenopalatine ganglion block with bupivacaine and dexamethasone alongside general anesthesia to see if it improves the surgeon's view and reduces postoperative pain for adults aged 21–60 having endoscopic trans-nasal pituitary surgery.

More General Anesthesia trials

Quick facts

Study typeInterventional
Ages21 Months to 60 Years
SexAll
Enrollment70 (estimated)
SponsorCairo University
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedJune 1, 2025
Main results expectedJune 1, 2026
Study endsJune 1, 2026
Registry record updatedMay 6, 2026
Trial IDNCT07569952 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 21–60 with ASA Physical Status I or II who are scheduled for elective endoscopic trans-nasal resection of a pituitary adenoma and have no contraindications to the block medications or anticoagulation.

Probably not a fit

Patients with higher surgical risk (ASA III–IV), those on blood-thinning medications, with allergies to study drugs, on chronic pain therapy, or who experience intraoperative vascular injury are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults undergoing elective endoscopic transsphenoidal hypophysectomy at Cairo University will receive an ultrasound-guided suprazygomatic sphenopalatine ganglion block with bupivacaine plus dexamethasone in addition to standard general anesthesia. The study will record the quality of the surgical field during the procedure and measure postoperative pain relief. Eligibility is limited to ASA I–II patients aged 21–60 who are not on anticoagulant therapy and have no relevant drug allergies. Outcomes will compare intraoperative visualization and early postoperative analgesia against standard anesthesia care.

Why it matters

Potential benefit: If successful, the block could give surgeons a clearer operating field and reduce postoperative pain, potentially lowering blood loss and improving recovery.

How similar studies have gone: Sphenopalatine ganglion block has been used successfully for nasal and facial pain and some nasal procedures, but its specific role in improving the surgical field during endoscopic pituitary surgery is limited and not well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age between 21 and 60 years.
* American Society of Anesthesiologists (ASA) Physical Status I or II.
* Undergoing elective endoscopic trans-nasal resection of pituitary adenoma.

Exclusion Criteria:

* Patient's refusal
* ASA Physical Status III or IV patients
* Patients receiving drugs influencing blood coagulation
* Allergy to any of the drugs utilized in this study
* History of chronic pain therapy
* Inadvertent intra-operative vascular injury

Where it's running

  • Cairo University
    Cairo, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.